BioDelivery Sciences Appoints Scott Plesha to President


RALEIGH, N.C., Dec. 20, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced the appointment of Scott Plesha, currently Senior Vice President of Sales and Marketing at BDSI, to the role of President, effective January 2, 2018. This coincides with the previously announced retirement of Dr. Mark A. Sirgo from his day-to-day role as President and Chief Executive Officer and his continuation as Vice Chairman of the Board of Directors. BDSI continues its search for a new Chief Executive Officer and anticipates an announcement regarding that executive role early next year, once the appropriate candidate is identified. Besides his new responsibilities, Mr. Plesha will continue to directly oversee the Sales and Marketing functions.

“Along with the Board of Directors, I want to congratulate Scott on this well-deserved promotion and associated expanded responsibilities. As he did at Salix Pharmaceuticals prior to joining BDSI, Scott has created an outstanding commercial organization as reflected in the success BDSI is experiencing behind BELBUCA,” said Dr. Sirgo. “BDSI will benefit from Scott’s leadership skills in this expanded role. We are also looking forward to completing our ongoing CEO search early next year once the appropriate candidate is identified. Scott’s appointment, and my support behind his efforts as I make my transition to the Board, gives BDSI time to identify the best person to lead BDSI. We have had a successful year with BELBUCA and are excited about the opportunities we have in front of us as we look to continue to grow BDSI and shareholder value into 2018.”

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.